Reuben Benjamin

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

Reuben Benjamin, Jérôme Larghero, Anne Daguenel-Nguyen · The Lancet · 2020 · 360 citations · Full text

Life Sciences, Hematology, Immunology +14

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Sebastian Grosicki, Maryana Simonova, Ivan Špıčka et al. · The Lancet · 2020 · 324 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

María‐Victoria Mateos, Katja Weisel, Valerio De Stefano et al. · Leukemia · 2022 · 240 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold et al. · The Lancet · 2018 · 236 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

Tolerance to rat monoclonal antibodies. Implications for serotherapy.

Reuben Benjamin, Stephen Cobbold, Mike Clark et al. · The Journal of Experimental Medicine · 1986 · 161 citations · Full text

Life Sciences, Immunology, Adaptive Immunity +12